Press Releases
Amarantus passe un accord d’option exclusive pour l’acquisition auprès de Lonza d’un substitut de peau artificielle pour le traitement des brûlures graves
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Amarantus to Host Business Update Conference Call on November 18, 2014
Amarantus Reports Third Quarter 2014 Financial Results and Enters Into Strategic Preferred Financing
Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees
Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa
Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)
Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference